Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H1 2018

June 2018 | 63 pages | ID: M143053E8E9EN
Global Markets Direct

Abstracts

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H1 2018

SUMMARY

Muscarinic Acetylcholine Receptor M2 (CHRM2) pipeline Target constitutes close to 8 molecules. The latest report Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H1 2018, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Muscarinic cholinergic receptor 2 is an acetylcholine receptor. It is expressed in various regions of the brain including the cerebellum, cerebral cortex, hippocampus, medulla, striatum, and thalamus, and in lung and prostate. It mediates smooth muscle contractility. Increase in M2 receptor has been associated with depression. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 2 respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones, Cardiovascular, Dermatology and Genetic Disorders which include indications Alzheimer's Disease, Overactive Bladder, Depression, Parkinson's Disease, Amnesia, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Axillary Hyperhidrosis, Bipolar Disorder (Manic Depression), Chromosomal Disorders, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Rett Syndrome, Schizophrenia, Stroke, Systolic Hypertension, Tuberous Sclerosis and Urinary Incontinence.

Furthermore, this report also reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M2 (CHRM2)
• The report reviews Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M2 (CHRM2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M2 (CHRM2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Overview
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Companies Involved in Therapeutics Development
Anavex Life Sciences Corp
Dare Bioscience Inc
FemmePharma Global Healthcare Inc
Karuna Pharmaceuticals Inc
TheraVida Inc
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Drug Profiles
(oxybutynin + pilocarpine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(trospium chloride + xanomeline) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANAVEX-141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANAVEX-273 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANAVEX-273 + donepezil hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THVD-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Dormant Products
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Discontinued Products
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Product Development Milestones
Featured News & Press Releases
Apr 17, 2018: Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX2-73 in Parkinson’s Disease Dementia and Provides Clinical Study Update for ANAVEX2-73 in Rett Syndrome
Apr 03, 2018: Dermavant Expands Pipeline and Strengthens Executive Team with Key Hires
Mar 07, 2018: Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)
Jan 16, 2018: Anavex Life Sciences Reports Potential Normalization of Hypertension with ANAVEX2-73 Published in The Journal of Clinical Hypertension
Nov 04, 2017: Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX2-73 at 2017 Clinical Trials on Alzheimer’s Disease Meeting
Oct 30, 2017: Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation's Parkinson's Disease Therapeutics Conference
Oct 27, 2017: Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017
Oct 12, 2017: Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX2-73 in Mild-to-Moderate Alzheimer’s disease Patients
Sep 05, 2017: Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX 2-73
Jul 20, 2017: Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board
May 22, 2017: Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome-Data Presented at Antiepileptic Drug Trials XIV 2017 Conference
May 19, 2017: Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings
Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis
Jan 19, 2017: Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017
Dec 15, 2016: Karuna Pharmaceuticals and PureTech Health Announce Positive Results from Tolerability Proof-of-Concept Study of KarXT, Being Developed for Schizophrenia and Alzheimers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Anavex Life Sciences Corp, H1 2018
Pipeline by Dare Bioscience Inc, H1 2018
Pipeline by FemmePharma Global Healthcare Inc, H1 2018
Pipeline by Karuna Pharmaceuticals Inc, H1 2018
Pipeline by TheraVida Inc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018

COMPANIES MENTIONED

Anavex Life Sciences Corp
Dare Bioscience Inc
FemmePharma Global Healthcare Inc
Karuna Pharmaceuticals Inc
TheraVida Inc